Becotatug Vedotin Plus Pucotenlimab Phase 2 Trial for Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
ClinicalTrials.gov Studies
Summary
A Phase 2 clinical trial (NCT07545083) has been registered to evaluate the effectiveness and safety of Becotatug Vedotin in combination with Pucotenlimab as neoadjuvant therapy for patients with locally advanced oral and oropharyngeal squamous cell carcinoma. The trial, listed under the intervention MRG003+Pucotenlimab, was registered with an April 22, 2026 status. Clinical investigators and oncology researchers may use this registry entry to identify ongoing studies in this therapeutic area.
“Conditions: Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This entry registers a Phase 2 clinical trial on ClinicalTrials.gov evaluating the combination of Becotatug Vedotin and Pucotenlimab for locally advanced oral and oropharyngeal squamous cell carcinoma. The trial is categorized as Phase 2 with an April 2026 status. Clinical investigators and oncology trial sponsors should note this registry entry for awareness of ongoing research in the ADC plus immunotherapy combination space for head and neck cancers.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)
Phase 2 NCT07545083 Kind: PHASE2 Apr 22, 2026
Abstract
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of Becotatug Vedotin with Pucotenlimab as a possible neoadjuvant therapyand for locally advanced oral/pharyngeal squamous cell carcinoma.
Conditions: Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Interventions: MRG003+Pucotenlimab
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.